Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioCryst Pharmaceuticals, Inc. - Common Stock (NQ:BCRX)

6.800 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioCryst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
BioCryst's Voluntary Pause Of Rare Blood Disorder Trial Turns Into FDA Clinical Hold ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: BioCryst Pharmaceuticals Q1 Earnings ↗
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Read Here Why Did BioCryst Stopped Enrollment In BCX9930 Studies In Rare Blood Disorder ↗
 
Via Benzinga
News headline image
Can Recent Catalysts Breakout BioCryst To New Highs? ↗
In today’s volatile markets, finding a biotech stock that isn’t purely speculative can be challenging, and yet BCRX may have what it takes. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
7 Top-Rated Biotech Stocks to Buy for Q2 ↗
In these tumultous economic times, look to sectors that are outside the turmoil. Each of these seven biotech stocks fit the bill. 
Via InvestorPlace
News headline image
What 4 Analyst Ratings Have To Say About BioCryst Pharmaceuticals ↗
Within the last quarter, BioCryst Pharmaceuticals (NASDAQ:BCRX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022 ↗
Upgrades 
Via Benzinga
News headline image
28 Biggest Movers From Yesterday ↗
Gainers HighPeak Energy, Inc. (NASDAQ: HPK) shares gained 31.76% to close at $28.83 on Wednesday, after CNBC’s Jim Cramer said the mid-cap company is an aggressive play on... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16 ↗
Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down... 
Via Benzinga
News headline image
Why BioCryst Pharmaceuticals Stock Is Falling ↗
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading lower Monday morning after BofA Securities downgraded the stock and Oppenheimer lowered its price target.  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Nasdaq Falls 150 Points; Crude Oil Rises 2% ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping more than 100 points on Friday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
News headline image
28 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million. TSR, Inc. (NASDAQ... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Mid-Day Market Update: Dow Jumps Over 200 Points; Sunshine Biopharma Shares Slide ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones surging more than 200 points on Friday. 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Edge Lower; US Wholesale Inventories Rise 2.5% In February ↗
U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping 100 points on Friday. 
Via Benzinga
News headline image
Why BioCryst Pharmaceuticals Stock Is Plunging Today ↗
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it ... 
Via Benzinga
News headline image
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
News headline image
BioCryst Continues To Develop A Strong Pipeline ↗
Investing in biotech stocks often comes with huge risks and rewards, as a company is dependent on its pipeline and royalty payments. 
Via Talk Markets
News headline image
BioCryst's Orladeyo Shows Long Term Benefit With Sustained Reductions in Attack Rates ↗
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) announced new long-term efficacy and safety data from the APeX-2 trial evaluating Orladeyo (berotralstat) for the... 
Via Benzinga
News headline image
Recap: BioCryst Pharmaceuticals Q4 Earnings ↗
BioCryst Pharmaceuticals (NASDAQ:BCRX) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
News headline image
BioCryst Hit 15-Year Highs But What's In Store Tomorrow For Earnings? ↗
By StoryTrading BioCryst’s (NASDAQ: BCRX) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic... 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Is BioCryst (BCRX) Ready to Breakout to New Highs on Recent Catalysts? ↗
By Ben Rabizadeh – Fundamentals well positioned with $1B peak sales forecast for Orladeyo and $300M influx of cash from royalty deals – Potential catalysts: update on Orladeyo sales with Q4 results on... 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 10 Years Ago, Here's How Much You Would Have Today ↗
BioCryst Pharmaceuticals (NASDAQ:BCRX) has outperformed the market over the past 10 years by 5.6% on an annualized basis. Buying $1,000 In BCRX: 10 years ago, an investor could... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.